Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

NCT04915248 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Plasmablastic Lymphoma

Interventions

DRUG: Daratumumab
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Fondazione Italiana Linfomi - ETS

Collaborators

[object Object]